Author:
Graier Thomas,Weger Wolfgang,Sator Paul-Gunther,Salmhofer Wolfgang,Gruber Barbara,Jonak Constanze,Kölli Claudia,Schütz-Bergmayr Martina,Vujic Igor,Ratzinger Gudrun,Häring Nina,Painsi Clemens,Prillinger Knut,Mlynek Alexander,Skvara Hans,Trattner Hannes,Tanew Adrian,Lichem Roland,Ellersdorfer Christina,Legat Franz,Gruber-Wackernagel Alexandra,Hofer Angelika,Schmiedberger Erich,Hoetzenecker Wolfram,Müllegger Robert,Saxinger Werner,Quehenberger Franz,Wolf Peter
Reference45 articles.
1. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies;Gladman;RMD Open,2018
2. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis;Kavanaugh;Arthritis Res Ther,2019
3. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2);Paul;Br J Dermatol,2015
4. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1);Papp;J Am Acad Dermatol,2015
5. Comparison of psoriasis guidelines for use of apremilast in the United States and Europe: a critical appraisal and comprehensive review;Ghamrawi;J Dermatolog Treat,2020
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献